Clinical Experience Program News Today

The 56-gene ctDNA panel is a key component of DefineMBC™, the company’s comprehensive blood biopsy for metastatic breast cancerSAN DIEGO--(BUSINESS WIRE)--Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (admi...

The firm is growing its sales, product marketing, and customer service teams for its multiomic metastatic breast cancer liquid biopsy test, DefineMBC.

Funding will accelerate commercial launch of DefineMBC™SAN DIEGO--(BUSINESS WIRE)--Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months. T...